2000
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease
Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Annals Of Oncology 2000, 11: 665-672. PMID: 10942053, DOI: 10.1023/a:1008396525292.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CD34Antineoplastic Combined Chemotherapy ProtocolsCarmustineCombined Modality TherapyCytarabineDisease-Free SurvivalEtoposideFemaleHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansL-Lactate DehydrogenaseMaleMelphalanMiddle AgedPrognosisRecurrenceTransplantation, AutologousConceptsProgression-free survivalHigh-dose BEAM chemotherapyPeripheral blood progenitor cellsAutologous PBPC transplantationTime of transplantationPrimary refractoryHodgkin's diseaseHigh-dose BEAMBEAM chemotherapyPBPC transplantationOverall survivalAutologous peripheral blood progenitor cell transplantationAutologous peripheral blood progenitor cellsPeripheral blood progenitor cell transplantationBlood progenitor cell transplantationSatisfactory progression-free survivalSevere non-hematologic toxicityWorse progression-free survivalPoor progression-free survivalAutologous PBPC infusionNon-hematologic toxicitiesTransplant-related complicationsConsecutive adult patientsElevated lactate dehydrogenaseRelapse/progression
1999
Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option
Seropian S, Nadkarni R, Jillella A, Salloum E, Burtness B, Hu G, Zelterman D, Cooper D. Neutropenic infections in 100 patients with non-Hodgkin’s lymphoma or Hodgkin’s disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplantation 1999, 23: 599-605. PMID: 10217191, DOI: 10.1038/sj.bmt.1701610.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAntibiotic ProphylaxisAntineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineDose-Response Relationship, DrugHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansLymphoma, Non-HodgkinMelphalanMiddle AgedNeutropeniaPodophyllotoxinRetrospective StudiesConceptsPeripheral blood progenitor cell transplantHigh-dose chemotherapyAbsolute neutrophil countProgenitor cell transplantCell transplantHodgkin's diseaseHodgkin's lymphomaHerpes simplex virus serologyHigh-dose BEAM chemotherapyGram-positive bacteremiaDuration of neutropeniaRisk of bacteremiaPeriod of neutropeniaMultivariate logistic regressionInvasive fungal infectionsRisk of developmentNumber of CD34Amphotericin therapyBEAM chemotherapyFebrile neutropeniaNeutropenic infectionOral ciprofloxacinWBC engraftmentProphylactic antibioticsCare visits